Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This represents two separate iron replacement products used to treat iron deficiency anemia, particularly in patients with chronic kidney disease receiving hemodialysis. **Sodium ferric gluconate complex** is a stable macromolecular complex with an apparent molecular weight of 289,000-440,000 daltons. It contains elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose. It works by replenishing iron stores so the body can make more red blood cells. **Iron sucrose** is a dark brown liquid solution administered intravenously when oral iron options cannot be used. It has ~20 mg of iron per mL of solution. After administration, it is transferred to ferritin, broken down in the liver, spleen, and bone marrow, and then either stored or taken up by plasma for transfer to hemoglobin. Both medications are used primarily in patients with chronic kidney disease on hemodialysis who are receiving supplemental epoetin therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium ferric gluconate + iron sucrose.